[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350652-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350652-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-prognostic-significance-of-b7-h3-expression-in-patients-with-advanced-colorectal-cancer","The prognostic significance of B7-H3 expression in patients with advanced colorectal cancer","","This study evaluates prognostic and immune-associated biomarkers in advanced colorectal cancer, focusing on B7-H3 and related markers. A colorectal tumor microarray from a multiracial cohort used quantitative immunohistochemistry to measure diagnostic markers (CK7, CK20, CDX2) and immune biomarkers (HHLA2, B7-H3, PD-L1). For metastatic cases, Kaplan-Meier and Cox regression assessed overall survival relationships. Low expression of both PD-L1 and B7-H3 correlated with better outcomes and supports future targeted research.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-prognostic-significance-of-b7-h3-expression-in-patients-with-advanced-colorectal-cancer/350652/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-prognostic-significance-of-b7-h3-expression-in-patients-with-advanced-colorectal-cancer/350652.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main aim of this study on colorectal cancer biomarkers?","Question",{"text":63,"@type":64},"To evaluate immune-associated biomarkers, especially B7-H3 expression and related markers, to predict clinical outcomes in patients with colorectal cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the biomarkers measured in the study?",{"text":68,"@type":64},"A colorectal tumor microarray (TMA) was analyzed using quantitative immunohistochemistry, determining both diagnostic markers (CK7, CK20, CDX2) and immune markers (HHLA2, B7-H3, PD-L1).",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about B7-H3 and PD-L1 expression and prognosis?",{"text":72,"@type":64},"In metastatic colorectal cancer, low expression of both B7-H3 and PD-L1 was associated with better overall survival, supporting their prognostic value.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350652,1790214177,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Huang et al. BMC Cancer (2026) 26:961 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16300-y](https://doi.org/10.1186/s12885-026-16300-y)  \nRESEARCH Open Access  \nThe prognostic significance of B7-H3 expression in patients with advanced colorectal cancer  \nYan Huang1,2, Ana Acuna-Villaorduna1,2,5, Radhika Gali1, Catarina Maia4, Keerthi Cedona1, Xingxing Zang2,  \nXiaohua Qi1, Wei Zhang1,2, Chenxin Zhang2, Juan Lin2, Qiang Liu1,2, Radhashree Maitra1,2,3† and Sanjay Goel1,2,6*†  \nAbstract  \nBackground Biomarkers, particularly prognostic and immune based, are lacking in colorectal cancer (CRC) . This study aimed to evaluate the expression of novel immune based biomarkers among patients with CRC to predict clinical outcomes.  \nMethods A CRC tumor microarray (TMA) was developed from a multiracial patient population, and  \nexpression of diagnostic markers (CK7, CK20, CDX2) and immune based (HHLA2, B7-H3, PD-L1) determined by immunohistochemistry (IHC) in a novel quantitative manner. Comprehensive clinical information was extracted. Among patients with metastatic (m) cancers, Kaplan Meier curves were plotted, and Cox proportional hazards regression analysis was performed to evaluate association with overall survival (OS) .  \nResults Among 388 patients, 150 had de novo metastatic disease, 108 experienced relapses from localized cancer, and 130 patients had cured localized disease. Racially/ethnically, 70 were non-Hispanic whites (NHW), 159 were non-Hispanic blacks (NHB), 147 Hispanic, and 12 Asian. The median age was 62 years, with a female predominance (53%) . Among the patients with metastatic CRC, that included those with relapses and with de novo metastatic CRC (n = 258), in a multivariable Cox proportional hazards model, left sidedness (HR 0 . 52; 95%CI 0.35 – 0 . 77, p \u003C 0. 001) and low expression of both PD-L1 and B7-H3 was associated with better OS (HR 1. 73; 95%CI 1.08–2. 76, p = 0 . 023) . Conclusion In this multiracial TMA of CRC, in a robust multivariable model, following REMARK guidelines, we validate our prior findings that low expression of both B7-H3 and PD-L1 is prognostic for OS among patients with mCRC.  \nGiven the rapid proliferation of B7-H3 targeted drug development in clinical trials, these findings may help create a platform for future research to delineate their predictive role in a bespoke therapeutic approach.  \nKeywords Colorectal cancer, Tissue microarray, B7-H3, PD-L1, HHLA2, CK7, Race, Ethnicity  \n†Radhashree Maitra and Sanjay Goel are equal contribution, and senior authors.  \n*Correspondence: Sanjay Goel [sanjay.goel@rutgers.edu](sanjay.goel@rutgers.edu)  \n1Montefiore Medical Center, Bronx, NY, USA  \n2Albert Einstein College of Medicine, Bronx, NY, USA 3Yeshiva University, New York City, NY, USA 4Jacobi Medical Center, Bronx, NY, USA  \n5Mount Sinai Cancer Center, New York City, NY, USA  \n6Robert Wood Johnson Medical School, Rutgers Cancer Institute, 195 Little Albany Street, New Brunswick, NJ 08903, USA  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http:/","cbCaitFJM4OauZhf","https://ap.wps.com/l/cbCaitFJM4OauZhf","pdf",1165110,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Précis (condensed abstract)\n# Introduction","[{\"question\":\"What was the main aim of this study on colorectal cancer biomarkers?\",\"answer\":\"To evaluate immune-associated biomarkers, especially B7-H3 expression and related markers, to predict clinical outcomes in patients with colorectal cancer.\"},{\"question\":\"How were the biomarkers measured in the study?\",\"answer\":\"A colorectal tumor microarray (TMA) was analyzed using quantitative immunohistochemistry, determining both diagnostic markers (CK7, CK20, CDX2) and immune markers (HHLA2, B7-H3, PD-L1).\"},{\"question\":\"What did the study find about B7-H3 and PD-L1 expression and prognosis?\",\"answer\":\"In metastatic colorectal cancer, low expression of both B7-H3 and PD-L1 was associated with better overall survival, supporting their prognostic value.\"}]","The prognostic significance of B7-H3 expression in patients with advanced colorectal cancer | PDF",1790090431,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f941d05993c6c59058af2051258cde4e.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99ee92849c5bf38a734f27c5d6babd50.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/004b6bf9187997d04e506472416f12f1.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfb20427b7759904cde21bc817978663.webp",980,1306]